ASCO 2026 pre-meeting materials highlighted multiple data sets across gastrointestinal and genitourinary cancers that investigators and clinicians will watch. The preview specifically pointed to cost-utility readouts from the phase 3 CHALLENGE exercise-program analysis in resected colon cancer, perioperative urothelial cancer data from KEYNOTE-B15/EV-304, and an atypical EGFR-mutant NSCLC cohort from CHRYSALIS-2. The CHALLENGE cost-utility analysis reported the structured exercise program as dominant versus health education materials in a base-case Canadian payer perspective, with lower total costs and gains in life-years and QALYs over a five-year horizon. Additional scenario analyses were described, with the report emphasizing implementation considerations for health systems. The preview does not include final full presentations but signals which trial readouts—clinical endpoints, safety, and economic value—are expected to shape near-term discussions at the meeting.